Browse the evidence

Obesity is a major contributor to type 2 diabetes, necessitating medication management for both conditions.

Addressing obesity is crucial in managing type 2 diabetes, and medication may be necessary.

Weight-loss medications, especially incretin mimetics, are effective for short- and long-term treatment of obesity-related hypertension.

Practitioners may consider prescribing incretin mimetics for effective management of obesity-related hypertension.

Surgical treatment of obesity achieves the greatest long-term weight loss compared to conservative treatment.

Practitioners should consider surgical options for patients seeking significant long-term weight loss.

A weight loss of 10% can already achieve a reduction in cardiovascular endpoints.

Practitioners should aim for at least a 10% weight loss in patients to improve cardiovascular health.

Orlistat and Liraglutide are currently available medication options for long-term obesity treatment in Germany.

Clinicians can prescribe Orlistat or Liraglutide for patients needing long-term obesity management.

Semaglutide shows effective weight reduction and HbA1c lowering in Type 2 Diabetes treatment.

Semaglutide can be recommended for patients with Type 2 Diabetes who also need to lose weight.

Glucagon-like peptide-1 receptor agonists have shown potential in treating obesity and reducing the risk of type 2 diabetes.

Healthcare providers may consider glucagon-like peptide-1 receptor agonists as a treatment option for obesity and diabetes risk reduction.

The category of weight loss had significantly greater decreases in hunger and increases in flexible dietary restraint compared to the categories of weight stability and weight gain.

Weight loss may be associated with improved hunger management and dietary restraint.

Treatment proposals for obesity must be individualized according to phenotyping.

Tailoring obesity treatment plans to individual profiles can enhance effectiveness.

Glucagon-like peptide-1 receptor agonists induce substantial and durable weight loss and improve obesity-related gastrointestinal outcomes.

Practitioners can consider GLP-1 receptor agonists as effective treatments for weight management and gastrointestinal health.

The partial inpatient obesity complex therapy in an internal medicine day clinic is an effective method for sustained weight reduction in patients with obesity III°.

Practitioners can consider this therapy as a viable option for managing severe obesity.

Responders achieved an absolute weight loss of 27.1 kg (approximately 20%), while non-responders lost 8.8 kg.

Practitioners can expect significant weight loss in a substantial portion of patients undergoing this therapy.

Bariatric interventions have shown the best therapeutic benefits in individuals with obesity.

Bariatric interventions should be considered as a primary treatment option for obesity.

GLP-1 receptor agonists have shown remarkable weight loss potential comparable to bariatric interventions.

GLP-1 receptor agonists may be a viable non-invasive alternative for weight loss in some patients.

Tirzepatide offers superior glycemic control and weight reduction compared to conventional GLP-1 receptor agonists.

Practitioners may consider Tirzepatide as a more effective option for managing glycemic control and weight in patients with T2DM.

Clinical trials have demonstrated effectiveness in lowering HbA1c and body weight.

Evidence from clinical trials supports the use of Tirzepatide for improving glycemic control and reducing body weight.

Exenatide combined with Metformin significantly reduced insulin resistance (HOMA-IR) by a mean difference of -0.9 (p < 0.001).

Practitioners may consider the combination of Exenatide and Metformin as an effective treatment for improving insulin resistance in women with PCOS.

Exenatide combined with Metformin reduced body mass index (BMI) by a mean difference of -0.4 (p = 0.03).

The combination therapy may assist in weight management for women with PCOS.

Several moderately sized meals spread over the day may result in greater muscle anabolism compared with the same amount of protein consumed in less frequent but bigger meals.

Practitioners should consider recommending multiple moderate protein meals throughout the day for better muscle anabolism.

Patients experienced an average weight loss of 16.06 ± 7.6 pounds at 12 weeks and 38.82 ± 11.4 pounds at 24 weeks.

Practitioners can expect significant weight loss in patients using compounded GLP-1 ± GIP agonists.

All secondary cardiometabolic outcomes improved significantly throughout the study.

Practitioners can consider compounded GLP-1 ± GIP agonists as effective for improving various cardiometabolic risk factors.

Several newer anti-obesity medications (AOMs) have been shown to reduce body weight significantly.

Clinicians can consider newer AOMs as effective options for weight management in obese patients.

Intensive lifestyle modification and medications that improve insulin resistance are key strategies for preventing type 2 diabetes (T2D).

Practitioners should focus on lifestyle changes and medications to prevent T2D.

The addition of 500 kcal·d −1 from whole foods/snacks in combination with a rigorous resistance training program promotes a weight gain of ~0.22 kg·wk −1, primarily as lean body mass, over 10 weeks in both male and female athletes.

Athletes looking to gain weight should consider increasing their caloric intake by 500 kcal·d −1 along with a structured resistance training program.